Azacitidine for the treatment of patients with acute myeloid leukemia

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine

(2010) R. Itzykson et al.   BLOOD

Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia

(2010) H. Kantarjian et al.   BLOOD

European Development of Clofarabine as Treatment for Older Patients With Acute Myeloid Leukemia Considered Unsuitable for Intensive Chemotherapy

(2010) Alan K. Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

Single-Agent Laromustine, A Novel Alkylating Agent, Has Significant Activity in Older Patients With Previously Untreated Poor-Risk Acute Myeloid Leukemia

(2009) Gary J. Schiller et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Clofarabine Monotherapy in Previously Untreated Older Adults With Acute Myeloid Leukemia and Unfavorable Prognostic Factors

(2009) Hagop M. Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

(2009) Pierre Fenaux et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid Leukemia

(2009) Amanda F. Cashen et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

(2009) Pierre Fenaux et al.   LANCET ONCOLOGY

Independent prognostic factors for AML outcome

(2009) D. Grimwade et al.   Hematology-American Society of Hematology Education Program

Current status of epigenetic treatment in myelodysplastic syndromes

(2008) Andrea Kuendgen et al.   ANNALS OF HEMATOLOGY

Demethylating agents in myeloid malignancies

(2008) Guillermo Garcia-Manero   CURRENT OPINION IN ONCOLOGY

Azacitidine and the beginnings of therapeutic epigenetic modulation

(2008) Kristen O'Dwyer et al.   EXPERT OPINION ON PHARMACOTHERAPY

Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia

(2008) J.-V. Malfuson et al.   HAEMATOLOGICA